PitchSend

Investor Presentaiton

Profit & Loss (ScinoPharm stand-alone) In NT$ million, except for EPS FY 2017 (Unaudited) FY 2016 (Audited) YOY Revenue 3,449 100% 3,889 100% -11% (note) Cost of Goods Sold (1,778) -52% (2,041) -52% 13% Gross Profit 1,671 48% 1,848 48% -10% Operating Expense (870) -25% (782) -20% -11% Operating Income 801 23% 1,066 27% -25% Non-operating Income, Net (313) -9% (244) -6% -28% Income before Tax 489 14% 822 21% -41% Net Income 422 12% 659 17% -36% EPS (NT$) 0.53 0.83 EBITDA 823 24% 1,178 30% -30% * Total outstanding shares were 790.739m units at 12/31/2017. 17 Note: 2016 vs 2017: 5.96% NTD appreciation against USD YoY ScinoPharm

View entire presentation